$INTI
Inhibitor Therapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223016967 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $508.5K $428.3K $93.50K
YoY Change 686.5% 358.11% -42.94%
% of Gross Profit
Research & Development $234.0K $201.4K $0.00
YoY Change 3704.76% -100.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $742.5K $629.7K $93.50K
YoY Change 948.61% 573.5% -44.26%
Operating Profit -$742.5K -$629.7K -$93.50K
YoY Change 948.61% 573.5% -44.26%
Interest Expense -$5.410K
YoY Change 220.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$654.5K -$539.6K -$98.91K
YoY Change 743.78% 445.55% -22.63%
Income Tax
% Of Pretax Income
Net Earnings -$654.5K -$539.6K -$98.91K
YoY Change 743.81% 445.54% -22.63%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 -$262.50
COMMON SHARES
Basic Shares Outstanding 171.8M shares 171.8M shares 376.9M shares
Diluted Shares Outstanding 172.0M shares 171.8M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.10M $10.78M $36.44K
YoY Change 40382.28% 29490.94% -56.72%
Cash & Equivalents $10.10M $10.78M $36.44K
Short-Term Investments
Other Short-Term Assets $58.01K $52.25K $24.71K
YoY Change 327.49% 111.45% -32.84%
Inventory
Prepaid Expenses $58.01K $52.25K
Receivables
Other Receivables
Total Short-Term Assets $10.16M $10.84M $61.14K
YoY Change 26273.64% 17621.93% -49.46%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $10.16M $10.84M $61.14K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $10.16M $10.84M $61.14K
YoY Change 26273.64% 17621.93% -55.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.75K $5.007K $321.7K
YoY Change -96.23% -98.44% -0.09%
Accrued Expenses $32.11K $73.44K $20.38K
YoY Change 18.31% 260.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $281.0K
YoY Change -100.0% -100.0% 440.38%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.86K $78.44K $830.2K
YoY Change -95.31% -90.55% 91.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% -3.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.86K $78.44K $830.2K
Total Long-Term Liabilities $3.000M $3.000M $3.000M
Total Liabilities $3.044M $3.078M $3.830M
YoY Change -22.65% -19.63% 8.3%
SHAREHOLDERS EQUITY
Retained Earnings -$46.95M -$46.29M
YoY Change -18.98%
Common Stock $54.06M $54.05M
YoY Change 7.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.114M $7.757M -$3.769M
YoY Change
Total Liabilities & Shareholders Equity $10.16M $10.84M $61.14K
YoY Change 26273.64% 17621.93% -55.72%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$654.5K -$539.6K -$98.91K
YoY Change 743.81% 445.54% -22.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$682.6K -$757.3K -$44.19K
YoY Change 1010.13% 1613.7% -51.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -$411.0K 50.00K
YoY Change -100.0% -922.0% -50.5%
NET CHANGE
Cash From Operating Activities -682.6K -$757.3K -44.19K
Cash From Investing Activities
Cash From Financing Activities 0.000 -$411.0K 50.00K
Net Change In Cash -682.6K -$1.168M 5.810K
YoY Change 5840.99% -20208.14% -36.36%
FREE CASH FLOW
Cash From Operating Activities -$682.6K -$757.3K -$44.19K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2022Q4 us-gaap Notes Payable Current Related And Nonrelated Party Status Extensible Enumeration
NotesPayableCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Revenues
Revenues
usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
usd
CY2022Q1 us-gaap Interest Expense Related And Nonrelated Party Status Extensible Enumeration
InterestExpenseRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
usd
CY2023Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2023Q1 INTI Accrued But Unpaid Dividends
AccruedButUnpaidDividends
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-13467
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0793665
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
900 West Platt St Suite 200
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Tampa
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33602-2173
CY2023Q1 dei City Area Code
CityAreaCode
813
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
864-2562
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
171793134 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10782941 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11951224 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
52248 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
23900 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
10835189 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11975124 usd
CY2023Q1 us-gaap Assets
Assets
10835189 usd
CY2022Q4 us-gaap Assets
Assets
11975124 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5007 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
145161 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
411000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73436 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122621 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
78443 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
678782 usd
CY2023Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3078443 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3678782 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171793134 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171793134 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
171793134 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
171793134 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
17179 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
17179 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54033084 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54033084 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46293517 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45753921 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10835189 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11975124 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
201398 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
428326 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93500 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
629724 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
93500 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-629724 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-93500 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
5410 usd
CY2023Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
90128 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910 usd
CY2022Q1 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
49315 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-539596 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-148225 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
171793134 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376858323 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8296342 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7756746 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-3620846 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-3769071 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-539596 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-98910 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
28348 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-3453 usd
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-189339 usd
CY2022Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
51269 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-757283 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44188 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50000 usd
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
411000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-411000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1168283 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5812 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11951224 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30626 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10782941 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36438 usd
CY2022Q1 INTI Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49315 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zTjMQtRAxIEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_z58R3XVCq7Z7">Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>

Files In Submission

Name View Source Status
0001493152-23-016967-index-headers.html Edgar Link pending
0001493152-23-016967-index.html Edgar Link pending
0001493152-23-016967.txt Edgar Link pending
0001493152-23-016967-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
inti-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
inti-20230331_cal.xml Edgar Link unprocessable
inti-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
inti-20230331_pre.xml Edgar Link unprocessable
inti-20230331_def.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending